ABBV 525
Alternative Names: ABBV-525; ABBV-MALT1Latest Information Update: 30 Jan 2024
At a glance
- Originator AbbVie
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in B-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 03 May 2023 CTP push 358905: phase I trial initiated
- 04 Apr 2023 Phase-I clinical trials in B-cell lymphoma (In adults, In the elderly, Monotherapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05618028)